Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $44.0M | $18.4M | $4.01M | $0.00 | — | — |
| Revenue growth | — | — | — | — | — | -58.2% | -78.2% | -100.0% | — | — |
| Gross profit | — | — | $0.00 | $0.00 | $9.45M | $12.6M | $3.36M | $0.00 | — | — |
| Gross margin | — | — | — | — | 21.5% | 68.4% | 83.8% | — | — | — |
| Operating income | -$52.8M | -$34.1M | -$21.0M | -$31.2M | -$18.3M | -$25.1M | -$34.5M | -$37.5M | -$42.5M | -$55.7M |
| Operating margin | — | — | — | — | -41.5% | -136.4% | -860.1% | — | — | — |
| Net income | -$52.8M | -$33.1M | -$21.1M | $669M | -$11.2M | -$17.4M | -$32.9M | -$24.6M | -$38.5M | -$45.5M |
| Net margin | — | — | — | — | -25.5% | -94.7% | -820.4% | — | — | — |
| EPS (diluted) | -$1.63 | -$0.95 | -$0.59 | $14.44 | -$0.36 | -$0.58 | -$1.08 | -$0.81 | -$1.26 | -$1.49 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46.0M | -$33.6M | -$16.5M | -$18.3M | -$65.1M | $69.4M | -$14.8M | -$18.7M | -$31.0M | -$39.9M |
| Capital expenditures | $4.75M | $1.41M | $122K | $204K | $3.73M | $3.52M | $585K | $362K | $1.30M | $289K |
| Free cash flow | -$50.8M | -$35.1M | -$16.7M | -$18.5M | -$68.9M | $65.9M | -$15.4M | -$19.1M | -$32.3M | -$40.2M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $14.0K | $0.00 | — |
| Dividends paid | — | — | — | $0.00 | $0.00 | $75.0M | $0.00 | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $34.3M | $31.8M | $15.8M | $715M | $237M | $237M | $157M | $200M | $173M | $126M |
| Total assets | $67.0M | $63.0M | $44.3M | $817M | $354M | $275M | $246M | $227M | $199M | $150M |
| Total liabilities | $7.99M | $2.81M | $2.95M | $61.2M | $5.11M | $5.79M | $5.70M | $7.77M | $16.8M | $9.73M |
| Shareholders' equity | $59.1M | $60.2M | $41.4M | $756M | $349M | $269M | $240M | $219M | $182M | $140M |
| Retained earnings | -$183M | -$217M | -$238M | $431M | $97.6M | $5.15M | -$27.7M | -$52.3M | -$90.8M | -$136M |
| Shares (wtd avg diluted) | 32.6M | 34.9M | 35.8M | 46.3M | 30.8M | 30.0M | 30.4M | 30.4M | 30.5M | 30.5M |
Every figure is extracted from XBiotech Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.